ClinicalTrials.gg
TerminatedNCT06470451FLASH2Updated Jul 13, 2026

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

A Phase 3 interventional study of Hypericin and Placebo in CTCL/ Mycosis Fungoides, CTCL and Mycosis Fungoides, sponsored by Soligenix. Terminated at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Soligenix · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
The Data Monitoring Committee conducted an interim analysis and recommended that the study be halted for futility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 360 studies in Mycosis Fungoides with a site in United States — 24 open to participants now, 36 under way, none of them phase 3. Mycosis Fungoides · United States.

Enrollment
53rd of 279
70 · median 32
Started
2025
with 2 others
Phase 3
19 of 360
none open now
Registered
350th of 360
by date

Among the 360 studies in Mycosis Fungoides with a site in United States, this one is the 53rd largest by enrollment of the 279 interventional ones that give a count, is one of 3 that started in 2025, is one of 19 in phase 3, and was the 350th registered.

Mycosis Fungoides

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

Browse Mycosis Fungoides studies →

Open to participants now

24 of the 360 studies in Mycosis Fungoides with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 360 studies in Mycosis Fungoides with a site in United States, or all of them as a file.
02

Study summary

To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

Read the detailed description

The primary objective of this Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible light.The study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks. Treated lesions will be covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light. All of the participant's lesions that are readily available for exposure to the visible light source will be treated and 3 to 5 index lesions in each patient will be prospectively identified and documented for modified Composite Assessment of Index Lesion Severity (mCAILS) evaluation. Participants will be followed every 4 weeks for a total of 12 weeks following their last light session.

03

Conditions studied

  • CTCL/ Mycosis Fungoides
  • CTCL
  • Mycosis Fungoides
  • Cutaneous T Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have a clinical diagnosis of cutaneous T-cell lymphoma (CTCL), Stage IA, Stage IB, or Stage IIA.
  • Patients with a minimum of three (3) evaluable, discrete lesions.
  • Patients willing to follow the clinical protocol and voluntarily give their written .
  • Female patients not pregnant or nursing and willing to undergo a pregnancy test within 30 days prior to treatment initiation.

Exclusion criteria

Exclusion Criteria:

  • History of sun and photosensitive dermatoses including porphyria, systemic lupus erythematosus, Sjögren's syndrome, xeroderma pigmentosum, polymorphous light eruptions, or radiation therapy within 30 days of enrolling.
  • History of allergy or hypersensitivity to any of the components of HyBryte.
  • A Screening with a >470 ms (corrected for heart rate using the Fridericia's formula).
  • All women of (WOCBP) and males with female partners who are WOCBP not willing to use effective .
  • Patients receiving topical or other topical treatments (eg, nitrogen mustard) on treated lesions for CTCL within 2 weeks of enrollment.
  • Patients receiving systemic steroids, psoralen UVA radiation therapy (PUVA), narrow band UVB light therapy (NB-UVB) or carmustine (BCNU) or other systemic therapies for CTCL within 4 weeks of enrollment.
  • Patients who have received electron beam irradiation within 3 months of enrollment.
  • Patients with a history of significant systemic .
  • Patients taking other drugs or drugs of abuse within 30 days of entry into this study.
  • Patients whose condition is spontaneously improving.
  • Patients with tumor stage or erythrodermic CTCL (stages IIB-IV).
  • Patients with extensive skin disease (>30% body surface area) who would be, in the judgement of the Principal Investigator, candidates for systemic treatment.
  • Patient has any condition that, in the judgment of the PI, is likely to interfere with participation in the study.
  • Prior participation in the current study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    HyBryte (0.25% Hypericin)

    HyBryte gel is applied twice weekly for 18 weeks.

    Drug: Hypericin

  • Placebo comparator
    Placebo

    Placebo gel is indistinguishable from HyBryte gel, and is applied twice weekly for 18 weeks.

    Drug: Placebo

Interventions

  • HyBryte gel (0.25% hypericin) is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.

    Also known as: HyBryte, SGX301

  • DrugPlacebo

    Placebo gel is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.

06

What researchers measure

Primary outcomes

  1. Number of Participants with a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) score

    A treatment response is defined as a ≥50% improvement in the cumulative mCAILS score of the index lesions at Week 18 when compared to the mCAILS score at baseline. The Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome.

    Time frame: 18 weeks

Secondary outcomes

  1. Patch Lesion Response Rates

    The proportion of patch lesions achieving a treatment response at Week 18. A treatment response is defined as a ≥50% improvement in mCAILS score when compared to the mCAILS score at baseline for individual lesions. The Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) score is measured as previously described.

    Time frame: 18 weeks

  2. Plaque Lesion Response Rates

    The proportion of plaque lesions achieving a treatment response at Week 18. A treatment response is defined as a ≥50% improvement in mCAILS score when compared to the mCAILS score at baseline for individual lesions. The Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) score is measured as previously described.

    Time frame: 18 weeks

07

Study locations

17 sites
  • Medical Dermatology Specialists
    Phoenix, Arizona 85006, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Dawes Fretzin Dermatology Group
    Indianapolis, Indiana 46256, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • Rochester Skin Lymphoma Medical Group
    Fairport, New York 14450, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Accellacare (PMG)
    Wilmington, North Carolina 28411, United States
  • Penn State Health Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Vanderbilt University
    Nashville, Tennessee 37212, United States
  • MD Anderson
    Houston, Texas 77030, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in May 2026, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2024
First posted
Jun 24, 2024
StartActual
Jan 7, 2025
Primary completionActual
May 22, 2026
CompletionActual
May 22, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06470451
Lead sponsor
Soligenix
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Jan 7, 2025
Primary completion
May 22, 2026
Completion
May 22, 2026
Last update
Jul 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hypericin

Start the discussion